Compare NHI & AKRO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | NHI | AKRO |
|---|---|---|
| Founded | 1991 | 2017 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Real Estate Investment Trusts | Biotechnology: Pharmaceutical Preparations |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.7B | 4.5B |
| IPO Year | 1991 | 2019 |
| Metric | NHI | AKRO |
|---|---|---|
| Price | $78.42 | $54.53 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 5 | 10 |
| Target Price | ★ $84.80 | $73.56 |
| AVG Volume (30 Days) | 179.5K | ★ 1.7M |
| Earning Date | 11-06-2025 | 11-07-2025 |
| Dividend Yield | ★ 4.69% | N/A |
| EPS Growth | ★ 8.88 | N/A |
| EPS | ★ 3.17 | N/A |
| Revenue | ★ $357,572,000.00 | N/A |
| Revenue This Year | $5.50 | N/A |
| Revenue Next Year | $11.38 | N/A |
| P/E Ratio | $24.75 | ★ N/A |
| Revenue Growth | ★ 8.40 | N/A |
| 52 Week Low | $65.13 | $21.34 |
| 52 Week High | $80.56 | $58.40 |
| Indicator | NHI | AKRO |
|---|---|---|
| Relative Strength Index (RSI) | 55.21 | 66.54 |
| Support Level | $77.57 | $54.22 |
| Resistance Level | $79.82 | $54.70 |
| Average True Range (ATR) | 1.30 | 0.14 |
| MACD | -0.02 | -0.11 |
| Stochastic Oscillator | 36.68 | 64.18 |
National Health Investors Inc is a housing and medical facility REIT. The company operates through two reportable segments, i.e., Real Estate Investments and Senior Housing Operating Portfolio (SHOP). The Real Estate Investments segment, which generates maximum revenue, consists of real estate investments and leases, mortgages, and other notes receivables in independent living facilities, assisted living facilities, entrance fee communities, senior living campuses, skilled nursing facilities, and a hospital. The SHOP segment is comprised of two ventures that own the operations of independent living facilities. The company's revenues are derived in the form of rental income, mortgage and other notes receivable interest income, and resident fees and services.
Akero Therapeutics Inc is a clinical-stage biotechnology company focused on developing and commercializing transformative treatments for serious metabolic diseases with high unmet medical needs. Its focus is nonalcoholic steatohepatitis (MASH), or NASH, a disease without any approved therapies. The company's product candidate efruxifermin is an FGF21 analog with properties that have the potential to address the core processes underlying NASH pathogenesis.